塞曲司特片剂随机双盲双模拟治疗支气管哮喘  

A double blind, double dummy, randomized, montelukast-controlled trial of seratrodast on asthma treatment

作　　者：杨晓春[1] 孙耕耘[1] 徐爱晖[1] 桂淑玉[1] 

机构地区：[1]安徽医科大学第一附属医院呼吸内科,230022

出　　处：《临床肺科杂志》2005年第5期554-555,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的评价塞曲司特片剂治疗支气管哮喘的疗效和安全性。方法采用随机、双盲、双模拟、阳性药(孟鲁司特)对照的方法。试验组20例,口服塞曲司特片剂80mg,qd,疗程8周。对照组20例,口服孟鲁司特10mg,qd,疗程8周。结果塞曲司特组和孟鲁司特组于治疗后临床症状及肺通气功能均有显著改善,但两组间无显著差异。塞曲司特不良反应轻微,发生率为10%。结论塞曲司特片剂是一种安全有效的治疗支气管哮喘的新药,治疗8周的疗效与孟鲁司特相当。Objective To evaluate the efficacy and safety of seratrodast in treating asthma patients.Methods A double-blind, double-dummy randomized, montelukast-controlled trial was performed. Forty patients were randomly assigned to receive seratrodast (80 mg/d), or montelukast (10 mg/d) for 8 weeks.Results During the treatment period, there were significant improvement in the changes in FEV1, peak expiratory flow (PEF) and clinical symptoms in the seratrodast and montelukast groups. There was not marked difference between the two groups. Seratrodast had less side effect.Conclusion Seratrodast is effective and safe in the treatment of asthma.

关 键 词：支气管哮喘 塞曲司特 双盲双模拟 片剂 随机 孟鲁司特 肺通气功能 临床症状 不良反应 安全性 对照组 治疗后 发生率 疗效 口服 疗程 

分 类 号：R562.25[医药卫生—呼吸系统] R974.3[医药卫生—内科学]